Corporate Information Archives - Page 15 of 21

PDMR Dealings

6.11.2018

RNS Number : 5353G

Faron Pharmaceuticals Oy

06 November 2018

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

PDMR Dealings

TURKU – FINLAND, 6 November 2018 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 6 November 2018 it was notified of the following PDMR dealing.

On 26 October 2018, Dr Matti Karvonen, VP Drug Development, Chief Medical Officer of Faron, had acquired 20,000 ordinary shares in Faron at a price of 82.90 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (“MAR”).

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Matti Karvonen
2	Reason for notification
a.	Position/Status	Person discharging managerial responsibilities – VP Drug Development, Chief Medical Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			82.90 GBPp	20,000

d.	Aggregated information – Aggregated Volume – Price	N/A N/A
e.	Date of the transaction	October 26, 2018
f.	Place of the transaction	London Stock Exchange, AIM Market

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker
Emma Earl, Freddy Crossley
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials and in 2017 received advice from US FDA to proceed directly to BLA submission following completion of EU and Japanese Phase III studies. There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Turn-on-your-Immunity or Turn-It may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.

END

DSHBFBATMBIMBPP

Director/PDMR Shareholding

18.9.2018

RNS Number : 0993B

Faron Pharmaceuticals Oy

18 September 2018

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

Person Closely Associated with PDMR Dealing

TURKU – FINLAND, 18 September 2018 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 17 September 2018 it was notified of the following person closely associated with PDMR dealing.

On 17 September 2018, a person closely associated with Dr. Matti Karvonen, Chief Medical Officer of Faron, had acquired 4,414 ordinary shares in Faron at a price of 100 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (“MAR”).

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Minja Pfeiffer
2	Reason for notification
a.	Position/Status	A person closely associated with the Chief Medical Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			100 pence	4,414

d.	Aggregated information – Aggregated Volume – Price	N/A N/A
e.	Date of the transaction	September 17, 2018
f.	Place of the transaction	London Stock Exchange, AIM Market

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

END

DSHFKFDBFBKKBCD

Holding(s) in Company

9.7.2018

RNS Number : 9946T

Faron Pharmaceuticals Oy

09 July 2018

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			Faron Pharmaceuticals Oy
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ:
3. Details of person subject to the notification obligation^iv
Name			Tom-Erik Lind
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from 3.)^v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached^vi:			05.07.2018
6. Date on which issuer notified (DD/MM/YYYY):			06.07.2018
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached	9,07 %			9,07 %	31,027,894
Position of previous notification (if applicable)	8,23 %			8,23 %

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
FI4000153309		2,813,835					9,07 %


SUBTOTAL 8. A		2,813,835					9,07 %

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi		Physical or cash settlement^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii				X
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv (please add additional rows as necessary)
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold






10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information^xvi

Place of completion	Tampere
Date of completion	09/07/2018

END

HOLFMGGNNLKGRZG

Holdings in Company

22.6.2018

TR-1: Standard form for notification of major holdings


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			Faron Pharmaceuticals Oy 7437009H31TO1DC0EB42
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ: Disclosure as per company’s Articles of Association						X
3. Details of person subject to the notification obligation^iv
Name			Legal & General Group Plc (Group) Legal & General Investment Management Limited (LGIM) Legal & General (Unit Trust Managers) Limited
City and country of registered office (if applicable)			1 Coleman St, London EC2R 5AA
4. Full name of shareholder(s) (if different from 3.)^v
Name			Legal & General Assurance Society (LGAS)
City and country of registered office (if applicable)			1 Coleman St, London EC2R 5AA
5. Date on which the threshold was crossed or reached^vi:			19 June 2018
6. Date on which issuer notified (DD/MM/YYYY):			21 June 2018
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached (LGIM)	0.37%	–		0.37%	31,027,894
Position of previous notification (if applicable) (LGIM)	1.53%	–		1.53%
Resulting situation on the date on which threshold was crossed or reached (UTM)	0.30%	–		0.30%	31,027,894
Position of previous notification (if applicable) (UTM)	1.26%	–		1.26%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
ORD NPV		–		116,000			–		0.37%
SUBTOTAL 8. A		116,000					0.37%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi		Physical or cash settlement^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv(please add additional rows as necessary)				x
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Legal & General Assurance Society (Direct)	0.06%		0.06%

Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Legal & General Assurance (Pensions Management) Limited (Direct)	–		–

Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management Limited (Indirect)	0.37%		0.37%

Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Legal & General (Unit Trust Managers) Limited (Indirect)	0.31%		0.31%

Legal & General Group (Direct/Indirect)	0.37%		0.37%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	0.37%		0.37%
Go ETF Solutions	–		–

10. In case of proxy voting, please identify:
Name of the proxy holder		N/A
The number and % of voting rights held		N/A
The date until which the voting rights will be held		N/A

11. Additional information^xvi
Notification using the total voting rights figure of 31,027,894

Place of completion	Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB
Date of completion	21/06/2018

Director/PDMR Shareholding

21.6.2018

RNS Number : 1926S

Faron Pharmaceuticals Oy

21 June 2018

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

PDMR Dealings and

Person Closely Associated with PDMR Dealings

TURKU – FINLAND, 21 June 2018 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 21 June 2018 it was notified of the following PDMR and persons closely associated dealings.

On 19 June 2018, Mr Matti Manner, the Non-Executive Director of Faron had acquired 15,500 ordinary shares in Faron at a price of 56 pence per ordinary share, and a person closely associated with him had acquired 7,900 ordinary shares in Faron at a price of 56 pence per ordinary share.

On 20 June 2018, Mr Yrjö Wichmann, Chief Financial Officer of Faron had acquired 5,200 ordinary shares in Faron at a price of 67 pence per ordinary share and on 21 June 2018, Dr. Pessi Honkasalo, Corporate Legal Counsel of Faron had acquired 1,500 ordinary shares in Faron at a price of 75 pence per ordinary share.

On 21 June 2018, Dr Matti Karvonen, Medical Director of Faron, had acquired 15,000 ordinary shares in Faron at a price of 56 pence per ordinary share and a person closely associated with him had acquired 31,000 ordinary shares in Faron at a price of 57 pence per ordinary share.

On 21 June 2018, Dr. Markku Jalkanen, Chief Executive Officer of Faron, had acquired 12,000 ordinary shares and a person closely associated with him had acquired 24,000 ordinary shares in Faron at a price of 71 pence per ordinary share. Also on 21 June 2018, Dr. Juho Jalkanen, Chief Development Officer of Faron had acquired 12,000 ordinary shares in Faron at a price of 71 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (“MAR”).

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Matti Manner Susanna Hedenström Yrjö Wichmann Pessi Honkasalo Matti Karvonen Minja Pfeiffer Markku Jalkanen Mehto Saima Kuolinpesä Juho Jalkanen
2	Reason for notification
a.	Position/Status	Person discharging managerial responsibilities / person closely associated – Non-Executive Director and a person closely associated with him – Chief Financial Officer – Corporate Legal Counsel – Medical Director and a person closely associated with him – Chief Executive Officer and a person closely associated with him – Chief Development Officer
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			56.00 GBPp 56.00 GBPp 67.00 GBPp 75.00 GBPp 56.00 GBPp 57.00 GBPp 71.00 GBPp 71.00 GBPp 71.00 GBPp	15,500 7,900 5,200 1,500 15,000 31,000 12,000 24,000 12,000

d.	Aggregated information – Aggregated Volume – Price	N/A N/A
e.	Date of the transaction	June 19, 2018, June 20, 2018 and June 21, 2018
f.	Place of the transaction	London Stock Exchange, AIM Market

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (“ARDS”). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

END

DSHFKDDPQBKDAAB

Director/PDMR Shareholding

21.6.2018

RNS Number : 1056S

Faron Pharmaceuticals Oy

21 June 2018

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

PDMR Dealing

TURKU – FINLAND, 21 June 2018 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 20 June 2018 it was notified that Dr Frank Armstrong, the Non-Executive Chairman of Faron, had acquired 13,300 ordinary shares in Faron at a price of 75 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (“MAR”).

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Frank Armstrong
2	Reason for notification
a.	Position/Status	Person discharging managerial responsibilities Non-Executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			75.00 GBPp	13,300

d.	Aggregated information – Aggregated Volume – Price	N/A N/A
e.	Date of the transaction	June 20, 2018
f.	Place of the transaction	London Stock Exchange, AIM Market

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (“ARDS”). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

END

DSHFKDDNABKKFAB

Holding(s) in Company

20.6.2018

TR-1: Standard form for notification of major holdings


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			Faron Pharmaceuticals Oy 7437009H31TO1DC0EB42
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ: Disclosure as per company’s Articles of Association						X
3. Details of person subject to the notification obligation^iv
Name			Legal & General Group Plc (Group) Legal & General Investment Management Limited (LGIM) Legal & General (Unit Trust Managers) Limited
City and country of registered office (if applicable)			1 Coleman St, London EC2R 5AA
4. Full name of shareholder(s) (if different from 3.)^v
Name			Legal & General Assurance Society (LGAS)
City and country of registered office (if applicable)			1 Coleman St, London EC2R 5AA
5. Date on which the threshold was crossed or reached^vi:			15 June 2018
6. Date on which issuer notified (DD/MM/YYYY):			19 June 2018
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached (LGIM)	1.53%	–		1.53%	31,027,894
Position of previous notification (if applicable) (LGIM)	2.98%	–		2.98%
Resulting situation on the date on which threshold was crossed or reached (UTM)	1.26%	–		1.26%	31,027,894
Position of previous notification (if applicable) (UTM)	2.90%	–		2.90%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights^ix					% of voting rights
		Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)			Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)		Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
ORD NPV		–		476,000			–		1.53%
SUBTOTAL 8. A		476,000					1.53%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi		Physical or cash settlement^xii			Number of voting rights	% of voting rights



					SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv(please add additional rows as necessary)				x
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Legal & General Assurance Society (Direct)	0.27%		0.27%

Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Legal & General Assurance (Pensions Management) Limited (Direct)	–		–

Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management Limited (Indirect)	1.53%		1.53%

Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Legal & General (Unit Trust Managers) Limited (Indirect)	1.26%		1.26%

Legal & General Group (Direct/Indirect)	1.53%		1.53%
Legal & General Investment Management (Holdings) Limited (Direct/Indirect)	1.53%		1.53%
Go ETF Solutions	–		–

10. In case of proxy voting, please identify:
Name of the proxy holder		N/A
The number and % of voting rights held		N/A
The date until which the voting rights will be held		N/A

11. Additional information^xvi
Notification using the total voting rights figure of 31,027,894

Place of completion	Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB
Date of completion	19/06/2018

Holdings in Company

18.6.2018

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)ⁱ

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedⁱⁱ:			FARON PHARMACEUTICALS OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer						X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)ⁱⁱⁱ:
3. Details of person subject to the notification obligation^iv
Name			CANACCORD GENUITY GROUP INC
City and country of registered office (if applicable)			VANCOUVER, CANADA
4. Full name of shareholder(s) (if different from 3.)^v
Name			DISCRETIONARY CLIENTS
City and country of registered office (if applicable)			As above
5. Date on which the threshold was crossed or reached^vi:			14 JUNE 2018
6. Date on which issuer notified (DD/MM/YYYY):			18 JUNE 2018
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights of issuer^vii
Resulting situation on the date on which threshold was crossed or reached	4.7566			4.7566	31,027,894
Position of previous notification (if applicable)	5.2686			5.2686

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached^viii
A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)	Number of voting rights^ix		% of voting rights
Class/type of shares ISIN code (if possible)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)	Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)	Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)
FI4000153309	N/A	1,475,875	N/A	4.7566

SUBTOTAL 8. A		1,475,875				4.7566

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument		Expiration date^x	Exercise/ Conversion Period^xi		Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument	Expiration date^x		Exercise/ Conversion Period ^xi	Physical or cash settlement^xii			Number of voting rights	% of voting rights



				SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer^xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity^xiv(please add additional rows as necessary)				X
Name^xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Canaccord Genuity Group Inc.	4.7566		4.7566
Canaccord Genuity Wealth Group Holdings Limited	4.7566		4.7566
Canaccord Genuity Wealth Group Holdings (Jersey) Limited	4.7566		4.7566
Hargreave Hale Ltd	4.7566		4.7566

10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information^xvi

Place of completion	BLACKPOOL, ENGLAND
Date of completion	18 JUNE 2018

Result of AGM

31.5.2018

RNS Number : 8891P

Faron Pharmaceuticals Oy

31 May 2018

Faron Pharmaceuticals Ltd

(“Faron” or the “Company”)

Results of the Annual General Meeting and Decisions of the Board of Directors

TURKU – FINLAND, 31 May 2018 – The Annual General Meeting of Faron Pharmaceuticals Ltd (LON: FARN) took place in Turku, Finland, today, 31 May 2018. The Annual General Meeting approved all the proposals of the Board of Directors and its committees, as set out in the notice of the Annual General Meeting published on 10 May 2018.

Decisions of the Annual General Meeting

The Annual General Meeting adopted the Financial Statements of the Company and resolved to discharge the members of the Board of Directors and the CEO of the Company from liability for the financial year 2017. No dividend for the financial year 2017 will be paid, and the losses of the Company for the financial year, amounting to EUR 21,060,638.95 (IFRS), will be carried forward to the reserve for invested unrestricted equity.

Composition and remuneration of the Board of Directors

The number of members of the Board of Directors was confirmed as nine (9). Frank Armstrong, Markku Jalkanen, Jonathan Knowles, Matti Manner, Huaizheng Peng, Yrjö Wichmann, Leopoldo Zambeletti, Gregory Brown and John Poulos were re-elected to the Board of Directors for a term that ends at the end of the next Annual General Meeting.

The Annual General Meeting resolved that an annual remuneration of EUR 35,000 will be paid to the Board members, in addition to which an annual remuneration of EUR 35,000 will be paid to the Chairman of the Board of Directors. In addition, a further annual remuneration of EUR 11,000 will be paid to the Chairman of the Audit Committee, a further annual remuneration of EUR 9,000 will be paid to the Chairman of the Remuneration Committee and a further annual remuneration of EUR 6,000 will be paid to the Chairman of the Nomination Committee. In addition, a further annual remuneration of EUR 6,000 will be paid to the Audit Committee members, a further annual remuneration of EUR 5,000 will be paid to the Remuneration Committee members and a further annual remuneration of EUR 3,000 will be paid to the Nomination Committee members. The meeting fees will be paid to the Board members as follows:

· A meeting fee of EUR 1,000 will be paid to Board members who are resident outside the European Union (“EU”) or the European Economic Area (“EEA”) per Board meeting where the Board member was physically present; and

· No meeting fees will be paid to Board members who are resident within the EU or the EEA or who were attending a Board meeting but not physically present.

In addition, all reasonable and properly documented expenses incurred in the performance of duties of the members of the Board of Directors will be compensated. No remuneration will be paid based on the Board membership of the CEO of the Company or a person serving the Company under a full-time employment or service agreement.

Amendment of the Articles of Association

The Annual General Meeting resolved that the following sentence be removed from Article 17.1 of the Company’s Articles of Association:

“Each shareholder shall make a Notification when he becomes a party to an agreement or an arrangement that upon implementation would result in the holdings of the shareholder reaching, exceeding or decreasing below any of above-mentioned thresholds.“

The Annual General Meeting further resolved that sections i) – k) be removed from Article 17.5 of the Company’s Articles of Association.

Auditor

PricewaterhouseCoopers Oy, Authorised Public Accountants, was re-elected as the Company’s auditor. PricewaterhouseCoopers Oy has appointed Panu Vänskä, Authorised Public Accountant, as the Auditor with principal responsibility for the completion of the audit. It was decided that the Auditor be remunerated in accordance with the invoice presented.

Authorisation to the Board of Directors to decide on the issuance of shares

The Board of Directors was authorised to resolve by one or several decisions on issuances of shares which authorisation contains the right to issue new shares or dispose of the shares in the possession of the Company. The authorisation consists of up to 6,206,000 shares in the aggregate, which corresponds to approximately 20 per cent of the existing shares and votes in the Company.

The authorisation does not exclude the Board of Directors’ right to decide on the issuance of shares in deviation from the shareholders’ pre-emptive rights. The authorisation can be used for material arrangements from the Company’s point of view, such as financing or implementing business arrangements, investments or for other such purposes determined by the Board of Directors in which case a weighty financial reason for issuing shares, and possibly deviating from the shareholders’ pre-emptive rights, exists.

The Board of Directors was authorised to resolve on all other terms and conditions of the issuance of shares. The authorisation will be effective until 30 June 2019.

Decisions of the Board of Directors

At the meeting of the Board of Directors held following the Annual General Meeting, Frank Armstrong was re-elected Chairman of the Board and Matti Manner was re-elected Deputy Chairman of the Board.

In addition, the Board of Directors elected the Chairmen and other members to the Board committees from among its members as follows:

· Leopoldo Zambeletti was elected the Chairman of the Audit Committee, and Matti Manner and Gregory Brown were elected as the other members of the Audit Committee.

· Matti Manner was elected the Chairman of the Nomination Committee, and Huaizheng Peng and Frank Armstrong were elected as the other members of the Nomination Committee.

· Frank Armstrong was elected as the Chairman of the Remuneration Committee, and Jonathan Knowles and John Poulos were elected as the other members of the Remuneration committee.

Minutes of the Annual General Meeting

The minutes of the Annual General Meeting will be available on the Company’s website from 14 June 2018 at the latest.

For more information, please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

investor.relations@faron.com

Consilium Strategic Communications

Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker

Freddy Crossley, Emma Earl, Ryan McCarthy

Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

END

RAGEADSFDDEPEFF

PDMR Shareholding

16.5.2018

RNS Number : 3448O

Faron Pharmaceuticals Oy

16 May 2018

Faron Pharmaceuticals Oy

(“Faron” or the “Company”)

PDMR Dealing

TURKU – FINLAND, 16 May 2018 – Faron Pharmaceuticals Ltd (“Faron”) (LON: FARN), the clinical stage biopharmaceutical company, announces that on 16 May 2018 it was notified that on 15 May 2018 Dr Jonathan Knowles, a Non-Executive Director of Faron has acquired 7,200 ordinary shares in Faron at an average price of 118.00 pence per ordinary share and 1,300 ordinary shares in Faron at an average price of 116.97 pence per ordinary share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Jonathan Knowles
2	Reason for notification
a.	Position/Status	Person discharging managerial responsibilities Non-Executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Oy
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares ISIN: FI4000153309
b.	Nature of the transaction	Purchase of ordinary shares
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			118.00 GBPp 116.97 GBPp	7,200 1,300

d.	Aggregated information – Aggregated Volume – Price	8,500 GBP 10,016.61
e.	Date of the transaction	May 15, 2018
f.	Place of the transaction	Turku

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com

Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com

Panmure Gordon (UK) Limited, Nomad and Broker
Freddy Crossley, Emma Earl, Ryan McCarthy
Phone: +44 207 886 2500

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company’s lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (“ARDS”). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm (“RAAA”). Faron’s second candidate Clevegen is a ground breaking preclinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology (“TIET”) may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHSFEFMMFASEII